Reply
Josh Levitsky, Elisa Gordon – 14 March 2020
Integrated Treatment of Alcohol Use Disorder in Patients With Alcohol‐Associated Liver Disease: An Evolving Story
Michael R. Lucey, Ashwani K. Singal – 14 March 2020
Cell‐Free Virus‐Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer
Chiao‐Ling Li, Ming‐Chih Ho, You‐Yu Lin, Sheng‐Tai Tzeng, Yun‐Ju Chen, Hsin‐Yung Pai, Ya‐Chun Wang, Chi‐Ling Chen, Yu‐Hsin Lee, Ding‐Shinn Chen, Shiou‐Hwei Yeh, Pei‐Jer Chen – 14 March 2020
Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation
Thoetchai (Bee) Peeraphatdit, Jennifer Wang, Matthew A. Odenwald, Shaomin Hu, John Hart, Michael R. Charlton – 13 March 2020 – Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies. The advent of ICIs has been a major breakthrough in the field of oncology, a fact recognized by the 2018 Nobel Prize in Physiology or Medicine being awarded for the discovery.
Drug‐Induced Liver Injury in GI Practice
Naemat Sandhu, Victor Navarro – 13 March 2020 – Although drug‐induced liver injury (DILI) is a rare clinical event, it carries significant morbidity and mortality, leaving it as the leading cause of acute liver failure in the United States. It is one of the most challenging diagnoses encountered by gastroenterologists. The development of various drug injury networks has played a vital role in expanding our knowledge regarding drug‐related and herbal and dietary supplement–related liver injury.
Disentangling Candidate Priority and Candidate Geography in Patients With Hepatocellular Carcinoma
Austin D. Schenk, W. Kenneth Washburn – 13 March 2020
Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation
Thoetchai (Bee) Peeraphatdit, Jennifer Wang, Matthew A. Odenwald, Shaomin Hu, John Hart, Michael R. Charlton – 13 March 2020 – Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies. The advent of ICIs has been a major breakthrough in the field of oncology, a fact recognized by the 2018 Nobel Prize in Physiology or Medicine being awarded for the discovery.
Intestinal Microbiome‐Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice
Anna Isaacs‐Ten, Marta Echeandia, Mar Moreno‐Gonzalez, Arlaine Brion, Andrew Goldson, Mark Philo, Angela M. Patterson, Aimee Parker, Mikel Galduroz, David Baker, Simon M. Rushbrook, Falk Hildebrand, Naiara Beraza – 13 March 2020
Nonhospice Palliative Care Within the Treatment of End‐Stage Liver Disease
Manisha Verma, Elliot B. Tapper, Amit G. Singal, Victor Navarro – 13 March 2020 – Palliative care (PC) that has evolved from a focus on end‐of‐life care to an expanded form of holistic care at an early stage for patients with serious illnesses and their families is commonly referred to as nonhospice PC (or early PC). Patients with end‐stage liver disease (ESLD) suffer from a high symptom burden and a deteriorated quality of life (QOL), with uncertain prognosis and limited treatment options.
Differential Associations of Circulating MicroRNAs With Pathogenic Factors in NAFLD
Ghideon Ezaz, Hirsh D. Trivedi, Margery A. Connelly, Claudia Filozof, Kellie Howard, Mark L.Parrish, Misung Kim, Mark A. Herman, Imad Nasser, Nezam H. Afdhal, Z. Gordon Jiang, Michelle Lai – 13 March 2020 – Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease driven by genetic and environmental factors. MicroRNAs (miRNAs) serve as pleiotropic post‐transcriptional regulators of cellular pathways.